Allen & Overy advised Shandong Boan Biotechnology Co., Ltd. on the deal. The transaction involed the spin-off from Luye Pharma Group (2186.HK) and a separate listing of...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here